-
Mashup Score: 19After Voxelotor: Navigating a Turning Point in Sickle Cell Therapy | ASH News Daily | American Society of Hematology - 1 month(s) ago
On September 25, 2024, a major chapter in sickle cell treatment came to an abrupt close. Voxelotor, granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2019, was celebrated as the first therapy to target the underlying pathophysiology of sickle cell disease (SCD). By stabilizing sickle hemoglobin in its oxygenated state, voxelotor reduced red cell sickling and its complications. The phase III HOPE trial, which showed a 44% hemoglobin response rate compared to placebo,
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Charging Toward New Therapies in Hematologic Malignancies | ASH News Daily | American Society of Hematology - 1 month(s) ago
Department of Haematology, Oxford University Hospitals, Oxford, U.K. Gimme fuel, gimme fire Gimme that which I desire As we gear up for the information-packed days of #ASH24, our mitochondria will be working overtime to fuel our minds to navigate the rapidly evolving clinical and scientific data — and our legs, for those inevitable sprints between distant sessions. The Scientific Workshop Mitochondria and Metabolism in Blood Cancer – From Discovery to Patients will showcase how energy-generating processes
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden f …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging - 4 month(s) ago
The term monoclonal gammopathy of clinical significance (MGCS) refers to a group of symptomatic monoclonal gammopathies that do not meet the diagnostic criteria for malignant plasma cell disorders, such as multiple myeloma or Waldenström macroglobulinemia. These symptoms are attributable to the paraneoplastic effects of monoclonal immunoglobulins that occur through diverse mechanisms. The presence of symptoms distinguishes MGCS from monoclonal gammopathy of undetermined significance, which lacks significant symptomatic presentation. The presentations of MGCS are manifold, adding to the diagnostic challenge. Clinical suspicion is key for accurate and timely diagnosis. Radiologic imaging can provide pivotal information to guide the diagnosis. In this review, we discuss MGCS from a radiology perspective and highlight pertinent imaging features associated with the disorders.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Check out Mayo Clinic's team fundraising page for Multiple Myeloma Research Foundation - 4 month(s) ago
Please support Mayo Clinic and Dr. Joselle Cook at the MMRF Walk/Run: Twin Cities. We are excited to be a part of this event again, and hope you will join our team!
Source: give.themmrf.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28
Blood Cancer Journal – Racial disparities in multiple myeloma and access to stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 8 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 8 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Hitting Us With Your Best Shot: the Best of ASH Malignant 2023 | ASH News Daily | American Society of Hematology - 1 year(s) ago
Division of Hematology, Mayo Clinic, Rochester, MN Ten years ago, at the 55 th ASH Annual Meeting and Exposition in New Orleans, the headline was, “Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma” since, for the first time, patients with relapsed refractory lymphoma and B-cell acute lymphoblastic leukemia (ALL) were treated with CD19 chimeric antigen receptors (CARs). The “Best of ASH 2013” also proclaimed imetelstat as the newest disease modifying agent for myelofibrosis which reversed
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Addressing the disparities: the approach to the African American patient with multiple myeloma - 1 year(s) ago
Blood Cancer Journal – Addressing the disparities: the approach to the African American patient with multiple myeloma
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
The unexpected withdrawal of #VOXELOTOR for sickle cell disease shocked everyone. 👉🏾MUST-READ interview w/ experts @DrAlexisThompsn @jstrous1 🚩attend Monday 1030am Room 33 convention center @ASH_hematology https://t.co/Sq4XsxYSID https://t.co/NxVrH74poj